These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 22666217)

  • 21. [New therapy concepts for castration-resistant prostate cancer: between hormone manipulation, targeted therapy and chemotherapy].
    Kübler H; Miller K
    Urologe A; 2013 Nov; 52(11):1517-8, 1520-1, 1524-6 passim. PubMed ID: 24166056
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New agents in metastatic prostate cancer.
    Choudhury AD; Kantoff PW
    J Natl Compr Canc Netw; 2012 Nov; 10(11):1403-9. PubMed ID: 23138168
    [TBL] [Abstract][Full Text] [Related]  

  • 23. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.
    Cornford P; Bellmunt J; Bolla M; Briers E; De Santis M; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; van der Poel HG; van der Kwast TH; Rouvière O; Wiegel T; Mottet N
    Eur Urol; 2017 Apr; 71(4):630-642. PubMed ID: 27591931
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Beyond sipuleucel-T: immune approaches to treating prostate cancer.
    Cheng ML; Fong L
    Curr Treat Options Oncol; 2014 Mar; 15(1):115-26. PubMed ID: 24402184
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Systemic therapy in men with metastatic castration-resistant prostate cancer: a systematic review.
    Loblaw DA; Walker-Dilks C; Winquist E; Hotte SJ;
    Clin Oncol (R Coll Radiol); 2013 Jul; 25(7):406-30. PubMed ID: 23587782
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer.
    Zhang T; Zhu J; George DJ; Armstrong AJ
    Expert Opin Pharmacother; 2015 Mar; 16(4):473-85. PubMed ID: 25534660
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer.
    Vignani F; Bertaglia V; Buttigliero C; Tucci M; Scagliotti GV; Di Maio M
    Cancer Treat Rev; 2016 Mar; 44():61-73. PubMed ID: 26907461
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New treatment options for patients with metastatic castration-resistant prostate cancer.
    Higano CS
    Cancer Treat Rev; 2012 Aug; 38(5):340-5. PubMed ID: 21944872
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Emerging molecularly targeted therapies in castration refractory prostate cancer.
    Patel JC; Maughan BL; Agarwal AM; Batten JA; Zhang TY; Agarwal N
    Prostate Cancer; 2013; 2013():981684. PubMed ID: 23819055
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potential use of custirsen to treat prostate cancer.
    Higano CS
    Onco Targets Ther; 2013; 6():785-97. PubMed ID: 23836992
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current treatment strategies for castration-resistant prostate cancer.
    Kim SJ; Kim SI
    Korean J Urol; 2011 Mar; 52(3):157-65. PubMed ID: 21461278
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Systemic Therapies for Metastatic Castration-Resistant Prostate Cancer: An Updated Review.
    Hatano K; Nonomura N
    World J Mens Health; 2023 Oct; 41(4):769-784. PubMed ID: 36792090
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recent advances in second-line treatment of castration-resistant prostate cancer.
    Ong M; Winquist E
    Curr Opin Support Palliat Care; 2011 Sep; 5(3):199-205. PubMed ID: 21734586
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sequencing of agents for castration-resistant prostate cancer.
    Hurwitz M; Petrylak DP
    Oncology (Williston Park); 2013 Nov; 27(11):1144-9, 1154-8. PubMed ID: 24575543
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Novel agents for the therapy of castration-resistant prostate cancer: overview of pivotal studies and new strategies to come].
    Ouzaid I; Ravery V; Pouessel D; Culine S
    Prog Urol; 2013 Jan; 23(1):1-7. PubMed ID: 23287477
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of metastatic castration-resistant prostate cancer: recent advances.
    Mukherji D; Eichholz A; De Bono JS
    Drugs; 2012 May; 72(8):1011-28. PubMed ID: 22621691
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Progress in emerging therapies for advanced prostate cancer.
    Oudard S
    Cancer Treat Rev; 2013 May; 39(3):275-89. PubMed ID: 23107383
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Taxane-based Combination Therapies for Metastatic Prostate Cancer.
    Corn PG; Agarwal N; Araujo JC; Sonpavde G
    Eur Urol Focus; 2019 May; 5(3):369-380. PubMed ID: 29275145
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer.
    MacVicar GR; Hussain MH
    Curr Opin Oncol; 2013 May; 25(3):252-60. PubMed ID: 23511665
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New therapies for castration-resistant prostate cancer: efficacy and safety.
    Beltran H; Beer TM; Carducci MA; de Bono J; Gleave M; Hussain M; Kelly WK; Saad F; Sternberg C; Tagawa ST; Tannock IF
    Eur Urol; 2011 Aug; 60(2):279-90. PubMed ID: 21592649
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.